[go: up one dir, main page]

WO2007061868A3 - Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors - Google Patents

Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors Download PDF

Info

Publication number
WO2007061868A3
WO2007061868A3 PCT/US2006/044720 US2006044720W WO2007061868A3 WO 2007061868 A3 WO2007061868 A3 WO 2007061868A3 US 2006044720 W US2006044720 W US 2006044720W WO 2007061868 A3 WO2007061868 A3 WO 2007061868A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stereotypic
serotonin reuptake
injurious
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/044720
Other languages
French (fr)
Other versions
WO2007061868A2 (en
Inventor
Louis Shuster
Nicholas H Dodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of WO2007061868A2 publication Critical patent/WO2007061868A2/en
Publication of WO2007061868A3 publication Critical patent/WO2007061868A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A combination of a specific serotonin reuptake inhibitor (SSRI) and an NMDA receptor antagonist can be used in methods of treatment, for reducing the frequency of stereotypic behaviors in animals and for reducing the frequency of analogous compulsive behaviors in humans, for example, those that have been said to be a manifestation of, or related to, obsessive-compulsive disorder.
PCT/US2006/044720 2005-11-17 2006-11-17 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors Ceased WO2007061868A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73771005P 2005-11-17 2005-11-17
US60/737,710 2005-11-17
US74280505P 2005-12-05 2005-12-05
US60/742,805 2005-12-05

Publications (2)

Publication Number Publication Date
WO2007061868A2 WO2007061868A2 (en) 2007-05-31
WO2007061868A3 true WO2007061868A3 (en) 2008-05-02

Family

ID=37992163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/044720 Ceased WO2007061868A2 (en) 2005-11-17 2006-11-17 Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors

Country Status (1)

Country Link
WO (1) WO2007061868A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567341B2 (en) 2014-09-15 2017-02-14 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EP3253761A4 (en) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists
KR102613179B1 (en) 2015-06-01 2023-12-14 뤼겐 홀딩스 (케이맨) 리미티드 3,3-Difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists
EP3544610A1 (en) 2016-11-22 2019-10-02 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York Compositions and methods against stress-induced affective disorders and their associated symptoms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002551A2 (en) * 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
US20020035105A1 (en) * 1997-05-07 2002-03-21 Caruso Frank S. Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035105A1 (en) * 1997-05-07 2002-03-21 Caruso Frank S. Composition and method combining an antidepressant with an NMDA receptor antagonist, for treating neuropathic pain
WO2000002551A2 (en) * 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
WO2005000216A2 (en) * 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CORIC ET AL: "Riluzole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial", BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 58, no. 5, 1 September 2005 (2005-09-01), pages 424 - 428, XP005015153, ISSN: 0006-3223 *
DOBLE A: "THE PHARMACOLOGY AND MECHANISM OF ACTION OF RILUZOLE", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 47, no. 6, 1996, pages S233 - S241, XP000910833, ISSN: 0028-3878 *
GRANT JON E ET AL: "Effectiveness of pharmacotherapy for pathological gambling: a chart review.", ANNALS OF CLINICAL PSYCHIATRY : OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF CLINICAL PSYCHIATRISTS SEP 2002, vol. 14, no. 3, September 2002 (2002-09-01), pages 155 - 161, XP002467929, ISSN: 1040-1237 *
MCDOUGLE C J ET AL: "Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics", ARCHIVES OF GENERAL PSYCHIATRY 1994 UNITED STATES, vol. 51, no. 4, 1994, pages 302 - 308, XP008088333, ISSN: 0003-990X *
PASQUINI M ET AL: "Memantine augmentation for refractory obsessive-compulsive disorder", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY 30 AUG 2006 UNITED STATES, vol. 30, no. 6, 30 August 2006 (2006-08-30), pages 1173 - 1175, XP002467930, ISSN: 0278-5846 *
ROGOZ Z ET AL: "Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 42, no. 8, June 2002 (2002-06-01), pages 1024 - 1030, XP002288820, ISSN: 0028-3908 *

Also Published As

Publication number Publication date
WO2007061868A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2005000216A3 (en) Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
PH12017500930A1 (en) Hsp90 inhibitor combinations
ZA200705879B (en) CGRP antagonists, method for production thereof, and their use as medicaments
WO2007089318A3 (en) Compositions and methods for reducing food cravings
PH12013500221A1 (en) Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
GB0514191D0 (en) Methods, apparatus and computer programs for optimized parsing and service invocation
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
WO2007120689A3 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
WO2008087491A3 (en) Method for treating or preventing symptoms of hormonal variations
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
BRPI0517091A (en) and method for treating a disease or condition by altering an opioid receptor-mediated response
WO2009145989A3 (en) Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2009117669A3 (en) Treatment with opioid antagonists and mtor inhibitors
BRPI0718469A2 (en) USE OF AN INTERLEUCIN 1 ANTAGONIST (IL-1), METHOD FOR TREATING, INHIBITING OR IMPROVING PSEUDOGOTA, USE OF ONE OR MORE THERAPEUTIC AGENTS, AND, PRODUCT.
GB2437145B (en) Method and apparatus for dynamically allocating resources used by software
TW200640529A (en) Composition for treating mental health disorders
AR058239A1 (en) METHODS TO TREAT ANXIETY DISORDERS
PL1751175T3 (en) Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
WO2007061868A3 (en) Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06837938

Country of ref document: EP

Kind code of ref document: A2